Blog
RSS FeedPosted by Michael Wonder on 25 May 2025
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA mutated, ER positive, HER2 negative, advanced breast cancer
23 May 2025 - Positive recommendation based on Phase 3 INAVO120 data showing Itovebi (inavolisib) in combination with palbociclib and fulvestrant ...
Posted by Michael Wonder on 23 May 2025
Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease
23 May 2025 - New treatment sparsentan has been found to slow down the progression of kidney damage, which will change ...
Posted by Michael Wonder on 22 May 2025
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
22 May 2025 - Dostarlimab, when used in combination with platinum-based chemotherapy, can be used as an option for the ...
Posted by Michael Wonder on 21 May 2025
New weekly treatment option approved for patients with haemophilia B
21 May 2025 - Final draft guidance published today recommends marstacimab (Hympavzi; Pfizer) for treating severe haemophilia B in patients ...
Posted by Michael Wonder on 21 May 2025
ICER to assess treatment for smoking cessation
20 May 2025 - Report will be subject of Midwest CEPAC meeting in January 2026; draft scoping document open to ...
Posted by Michael Wonder on 20 May 2025
Redefining value assessment and healthcare funding priorities for medicines: the journey to patient-centric decision making in APAC – a systematic literature review
14 May 2025 - This study explored patient involvement in health care decision-making in the Asia-Pacific region by identifying roles and ...
Posted by Michael Wonder on 16 May 2025
ICER publishes final evidence report on treatment for retinitis pigmentosa
15 May 2025 - Independent appraisal committee voted that current evidence is adequate to demonstrate a net health benefit of ...
Posted by Michael Wonder on 15 May 2025
Deal agreed for continued access to life-changing treatment for rare inherited disease
14 May 2025 - NICE is consulting on draft guidance for cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2, ...
Posted by Michael Wonder on 15 May 2025
Health inequalities - an update to NICE’s methods for health technology evaluation
14 May 2025 - Our new modular update focuses on how we consider health inequalities when evaluating technologies for use in ...
Posted by Michael Wonder on 13 May 2025
SMC - May 2025 decisions
13 May 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 12 May 2025
Erdafitinib for the treatment of patients with unresectable or metastatic urothelial cancer with an FGFR3 alteration after a PD-1 or PD-L1 inhibitor
12 May 2025 - Erdafitinib is recommended as an option for the treatment of adults with unresectable or metastatic urothelial cancer ...
Posted by Michael Wonder on 09 May 2025
Adagrasib for previously treated patients with advanced KRAS G12C mutation positive non-small-cell lung cancer
9 May 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 May 2025
DoH publishes revised agenda for the July 2025 PBAC meeting
9 May 2025 - The agenda for the July 2025 PBAC meeting has been updated. ...
Posted by Michael Wonder on 09 May 2025
Osimertinib mesylate in combination with pemetrexed disodium heptahydrate and platinum-based chemotherapy for patients with advanced EGFR mutation positive non-small-cell lung cancer (final guidance)
8 May 2025 - Osimertinib mesylate, when used in combination with pemetrexed disodium heptahydrate and platinum-based chemotherapy, is recommended as an ...
Posted by Michael Wonder on 08 May 2025
Brentuximab vedotin in combination with chemotherapy for the treatment of patients with stage 3 or 4 CD30 positive Hodgkin lymphoma
7 May 2025 - Brentuximab vedotin, when used in combination with doxorubicin hydrochloride, dacarbazine and vinblastine sulphate is recommended as an ...